MENS (Jyong Biotech Limited) Net Profit

Corporate emblem and logo of jyongbio.com (MENS)

Inelastic demand for the unique plant-based pharmaceuticals of Jyong Biotech Ltd (MENS) contrasts with management's focus on expanding distribution networks. The company's net operating result allows for a balance of these factors, while -0.01 reflects the latest metric value. However, reliance on third-party manufacturing creates risks that management seeks to mitigate by sourcing new reliable contractors.

MENS (Jyong Biotech) Company Net Income history from 06/18/2025 to 10/31/2026

Financial and market metric breakdowns for Jyong Biotech (MENS)

- price and consensus price forecast:
Stock Quotes Jyong Bio|MENS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Jyong Bio|MENS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Jyong Biotech|MENS - Company Book Value|Market-to-Book Ratio jyongbio.com|MENS - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Jyong Biotech Ltd|MENS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Jyong Biotech Limited|MENS - Company Aggregate Debts|Debts to Book Value Jyong Bio|MENS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Jyong Biotech|Intermediate Liquidity Ratio jyongbio.com
- net income and valuation multiples indicators:
MENS - Net Income
Fundamental valuation:MENS Jyong Bio
Flagship merchandise of Jyong Biotech Limited

Investors are assessing the potential of Jyong Biotech Ltd (MENS) through the lens of the efficiency of its innovative developments in men's health. The daily calculation of the company's actual profit eliminates the reporting time lag, capturing daily operational dynamics and confirming the commercial sustainability of science-backed solutions, which allows this asset to be classified as a fundamentally significant biopharmaceutical tool.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income LGND (Ligand)|AMRX (Amneal Pharmaceuticals, Inc.) - Final Profit|Company Net Income Perrigo Company PRGO|Alvotech Biopharmaceuticals (ALVO) - Company Net Income|LQDA: Net Income|glpg.com - Profit After Payment of Taxes|ANIP: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Company Net Income Aquestive Therapeutics, Inc. AQST|Profit After Payment of Taxes SCPH (scPharmaceuticals, Inc.)|TECX: Net Income|Company Net Income Tonix Pharmaceuticals Holding|sxtchina.com (SXTC) - Company Net Income|Company Net Income Eupraxia Pharmaceuticals Inc. (EPRX)|Company Net Income BioHarvest Sciences Inc.|Company Profit EXOZ (Invizyne Technologies)|Net Profit ORMP|enterabio.com (ENTX) - Annual Net Income|MindWalk Holdings - Net Income|Final Profit ABVC|Cumberland Pharmaceuticals Inc. - Net Profit|QNTM: Company Net Income|FGEN: Net Profit|TELO - Net Financial Result|Company Net Income Rani Therapeutics Holdings|Company Net Income Synergy CHC Corporation SNYR|Net Income RLYB (Rallybio Corporation)|Profit After Payment of Taxes LEXX|Net Profit PULM (Pulmatrix Corp)|Pheton Holdings Limited (PTHL) - Company Net Income|Aptorum - Net Profit|lyratherapeutics.com (LYRA) - Net Income|IBO: Net Profit|TNF Pharmaceuticals, Inc. - Final Profit|Net Income YCBD|PRFX: Final Profit|Company Net Income Altamira Therapeutics (CYTO)|Company Net Income LIPO (lipella.com)|OptiNose - Net Income|Profit After Payment of Taxes PIRS (Pieris Pharmaceuticals Inc)|Procaps Group SA - Net Profit|PTPI (Petros Pharma) - Company Profit|Qilian International (QLI) - Company Net Income|Net Income acelyrin.com|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit